Renalytix Ai Plc-adr (RNLX)
$0.6995
Insights on Renalytix Ai Plc-adr
Increasing Revenue
Revenue is up for the last 2 quarters, 459.0K → 709.0K (in $), with an average increase of 35.3% per quarter
Increasing Net Profit
Netprofit is up for the last 5 quarters, -12.02M → -8.48M (in $), with an average increase of 9.3% per quarter
Vs HQY
In the last 1 year, Healthequity Inc has given 41.8% return, outperforming this stock by 109.7%
Performance
- $0.70$0.74$0.70
0.22%
Downside
Day's Volatility :5.63%
Upside
5.42%
- $0.24$4.04$0.70
65.01%
Downside
52 Weeks Volatility :93.94%
Upside
82.67%
Returns
| Period | Renalytix Ai Plc-adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 157.41% | -0.4% | 0.0% |
6 Months | -32.14% | 9.6% | 0.0% |
1 Year | -67.26% | 3.9% | -1.3% |
3 Years | -97.34% | 12.8% | -22.1% |
Highlights
Market Capitalization | 50.6M |
Book Value | - $0.08 |
Earnings Per Share (EPS) | -0.9 |
Wall Street Target Price | 4.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1175.6% |
Return On Assets TTM | -88.32% |
Return On Equity TTM | -651.4% |
Revenue TTM | 2.4M |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | -40.5% |
Gross Profit TTM | 720.0K |
EBITDA | -37.8M |
Diluted Eps TTM | -0.9 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.34 |
EPS Estimate Next Year | -0.27 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | -0.08 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 471.84%
Technicals Summary
Sell
Neutral
Buy
Renalytix Ai Plc-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Renalytix Ai Plc-adr | -17.66% | -32.14% | -67.26% | -97.34% | -97.34% |
 Solventum Corp | -10.17% | -10.17% | -10.17% | -10.17% | -10.17% |
 Veeva Systems Inc. | -13.23% | 2.01% | 6.81% | -29.07% | 45.79% |
 Ge Healthcare Technologies Inc. | -4.5% | 31.75% | -3.96% | 39.38% | 39.38% |
 Healthequity Inc | 2.28% | 12.84% | 44.24% | 10.42% | 17.63% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Renalytix Ai Plc-adr | NA | NA | NA | -0.34 | -6.51 | -0.88 | NA | -0.08 |
Solventum Corp | NA | NA | NA | 0.0 | 0.12 | 0.08 | NA | NA |
Veeva Systems Inc. | 61.8 | 61.8 | 1.35 | 4.76 | 0.13 | 0.05 | NA | 28.8 |
Ge Healthcare Technologies Inc. | 27.79 | 27.79 | 20.11 | 4.3 | 0.19 | 0.06 | 0.0 | 15.67 |
Healthequity Inc | 126.39 | 126.39 | 2.29 | 2.19 | 0.03 | 0.03 | NA | 23.63 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Renalytix Ai Plc-adr | Buy | $50.6M | -97.34% | NA | 0.0% |
Solventum Corp | NA | $11.7B | -10.17% | NA | 16.42% |
Veeva Systems Inc. | Buy | $32.0B | 45.79% | 61.8 | 22.24% |
Ge Healthcare Technologies Inc. | Buy | $38.6B | 39.38% | 27.79 | 8.02% |
Healthequity Inc | Buy | $7.0B | 17.63% | 126.39 | 5.57% |
Institutional Holdings
CVI Holdings LLC
2.29%Gilder Gagnon Howe & CO LLC
1.76%Pinnacle Associates Inc
1.69%Pentwater Capital Management LP
1.40%Tejara Capital Ltd
0.80%CI Private Wealth LLC
0.67%
Corporate Announcements
Renalytix Ai Plc-adr Earnings
Renalytix Ai Plc-adr’s price-to-earnings ratio stands at None
Read More
Company Information
renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev
Organization | Renalytix Ai Plc-adr |
Employees | 0 |
CEO | Mr. James R. McCullough M.B.A. |
Industry | Technology Services |
